Erschienen in:
31.03.2020 | Images that Teach
Switching from clopidogrel to prasugrel resolves vascular inflammation in patients receiving long-term aspirin plus clopidogrel therapy after coronary stent implantation
verfasst von:
Munehisa Bekki, MD, Nobuhiro Tahara, MD, PhD, Atsuko Tahara, MD, Shoko Maeda-Ogata, MD, Yoichi Sugiyama, MD, Akihiro Honda, MD, PhD, Sachiyo Igata, PhD, Atsushi Harada, BPharm, Yuji Hirakawa, BA, Seiji Kurata, MD, PhD, Kiminori Fujimoto, MD, PhD, Toshi Abe, MD, PhD, Yoshihiro Fukumoto, MD, PhD, Takafumi Ueno, MD, PhD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
Sufficient inhibition of platelet aggregation after percutaneous coronary intervention is desirable for patients with stent implantation.
1 Here, we describe the effect of switching from clopidogrel to prasugrel on vascular inflammation using serial [
18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) combined with computed tomography (CT) in 2 patients receiving a long-term aspirin plus clopidogrel dual antiplatelet therapy (DAPT) after coronary stent implantation. In both cases, platelet reactivity (P2Y
12 reaction units: PRU) indicated insufficient efficacy of DAPT. All medications, such as aspirin, hypertensive medications, diabetic medications, and statins except for clopidogrel were not altered during the follow-up period. …
